Investors & Media
6 Oct. 2016

Kamada Announces Extension of GLASSIA® Supply and Distribution Agreement with Shire with Minimum $237 Million of Revenue for the Years 2017 to 2020

NESS ZIONA, Israel – October 6, 2016 – Kamada Ltd. (NASDAQ and TASE: KMDA), a
plasma-derived protein therapeutics company focused on orphan indications, announced
today the extension of the strategic partnership with Shire plc (LSE: SHP, NASDAQ: SHPG)
for GLASSIA® . Minimum revenue for GLASSIA in the extended agreement for the years
2017 to 2020 will reach approximately $237 million and may be expanded to $288 million
during that period. Kamada will now continue to produce GLASSIA through 2020 for Shire,
after which Shire may produce the product at their facility and pay Kamada established
royalty rates. This represents the fourth time the companies have extended the contract for
manufacturing supply of GLASSIA since the start of the strategic relationship in 2010.
“The extension of our strategic partnership agreement with Shire is a testament to the
growing market share and increasing demand for GLASSIA in the U.S., and to the strong
strategic relationship between Kamada and Shire,” said Amir London, Kamada's Chief
Executive Officer. “This minimum commitment by Shire further strengthens our
confidence in achieving the expected $100 million revenue target in 2017 and represents
further growth in the following years. We have the capacity to support this increasing
demand for GLASSIA and appreciate the trust of Shire in our capabilities, which are
demonstrated in our supply agreement, as well as our co-development projects for IV-AAT
for additional indications, including Graft-versus-Host Disease and lung transplant.”
Approved in 2010, GLASSIA is the first and only liquid ready-to-use augmentation product
approved for the treatment of clinically evident emphysema due to severe AAT
deficiency. Kamada and Shire (Baxter at the time) entered into an exclusive strategic
cooperation agreement for the distribution and license of GLASSIA in 2010. Under the
terms of the agreement, Shire is the exclusive distributor of GLASSIA in the U.S., Canada,
Australia and New Zealand, and is licensed to produce GLASSIA using Kamada's technology
at a Shire facility for sales in those countries.

GLASSIA is the first available ready-to-infuse liquid alpha1-proteinase inhibitor and is
indicated as a chronic augmentation and maintenance therapy in adults with clinically
evident emphysema due to severe congenital AAT deficiency. GLASSIA is administered
intravenously once a week to augment the levels of AAT in the blood. AAT is a protein
derived from human plasma with known and newly discovered therapeutic roles given its
immunomodulatory, anti-inflammatory, tissue protective and antimicrobial properties.
GLASSIA is approved by the FDA and is marketed through a strategic partnership with
Baxalta in the United States.
Please see the full prescribing information for GLASSIA at:
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and
has a commercial product portfolio and a robust late-stage product pipeline. The Company
uses its proprietary platform technology and know-how for the extraction and purification
of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified,
liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived
from human plasma with known and newly-discovered therapeutic roles given its
immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties.
The Company's flagship product is GLASSIA®, the first and only liquid, ready-to-use,
intravenous plasma-derived AAT product approved by the U.S. Food and Drug
Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership
with Baxalta (now part of Shire plc) and in other counties through local distributors. In
addition to GLASSIA®, Kamada has a product line of seven other pharmaceutical products
administered by injection or infusion, that are marketed through distributors in more than
15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and
Asia. Kamada has five late-stage plasma-derived protein products in development,
including an inhaled formulation of AAT for the treatment of AAT deficiency for which a
MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in
Europe. Kamada has also completed its Phase 2 clinical trials in the U.S for the treatment of
AAT deficiency with inhaled AAT. In addition, Kamada's intravenous AAT is in development
for other indications such as type-1 diabetes, GvHD and prevention of lung transplant
rejection. Kamada also leverages its expertise and presence in the plasma-derived protein
therapeutics market by distributing more than 10 complementary products in Israel that
are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the
U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of
1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that are not historical
facts, such as statements regarding assumptions and results related to financial results
forecast, commercial results, timing and results of clinical trials and EMA and U.S. FD

submissions and authorizations. Forward-looking statements are based on Kamada's
current knowledge and its present beliefs and expectations regarding possible future
events and are subject to risks, uncertainties and assumptions. Actual results and the
timing of events could differ materially from those anticipated in these forward-looking
statements as a result of several factors including, but not limited to, unexpected results of
clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional
competition in the AATD market or further regulatory delays. The forward-looking
statements made herein speak only as of the date of this announcement and Kamada
undertakes no obligation to update publicly such forward-looking statements to reflect
subsequent events or circumstances, except as otherwise required by law.
Gil Efron
Chief Financial Officer
Bob Yedid
LifeSci Advisors
This website uses cookies to track the site’s performance and improve user experience.
By using our website you consent to all cookies in accordance with our Privacy Policy.